← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$3.66
Model IV—
P/IV—
Limited data — see page
LKFT
Lakefront Biotherapeutics NV
Valuation N/A
Healthcare Risk 37 · Moderate
Price$26.81
Model IV—
P/IV—
Limited data — see page
LKSP
Lake Superior Acquisition Corp
Valuation N/A
Financial Services Risk 46 · Elevated
Price$10.22
Model IV—
P/IV—
Limited data — see page
LKSPR
Lake Superior Acquisition Corp
Valuation N/A
Financial Services Risk 31 · Moderate
Price$1.20
Model IV—
P/IV—
Limited data — see page
LLYVA
Liberty Live Holdings, Inc.
Valuation N/A
Communication Services
Price$93.98
Model IV—
P/IV—
Market implies +29.9%/yr vs model +12.2% · above model
LLYVK
Liberty Live Holdings, Inc.
Valuation N/A
Communication Services
Price$97.36
Model IV—
P/IV—
Market implies +30.4%/yr vs model +12.2% · above model
LMND
Lemonade, Inc.
Valuation N/A
Financial Services Risk 40 · Elevated
Price$50.03
Model IV—
P/IV—
Limited data — see page
LMRI
Lumexa Imaging Holdings, Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$11.49
Model IV—
P/IV—
Limited data — see page
LNAI
Lunai Bioworks Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.38
Model IV—
P/IV—
Limited data — see page
LND
BrasilAgro - Brazilian Agricultural Real Estate Co
Valuation N/A
Basic Materials Risk 54 · Elevated
Price$3.71
Model IV—
P/IV—
Limited data — see page
LNKS
Linkers Industries Ltd
Valuation N/A
Technology Risk 31 · Moderate
Price$1.00
Model IV—
P/IV—
Limited data — see page
LNZA
LanzaTech Global, Inc.
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$6.06
Model IV—
P/IV—
Market implies +67.9%/yr vs model +8.0% · above model
LOAR
Loar Holdings Inc.
Valuation N/A
Industrials Risk 47 · Elevated
Price$66.51
Model IV—
P/IV—
Limited data — see page
LOCL
Local Bounti Corporation/DE
Valuation N/A
Basic Materials Risk 73 · High
Price$1.30
Model IV—
P/IV—
Market implies +33.4%/yr vs model +5.0% · above model
LODE
Comstock Inc.
Valuation N/A
Basic Materials Risk 29 · Moderate
Price$2.82
Model IV—
P/IV—
Market implies +56.9%/yr vs model +8.0% · above model
LOKV
Live Oak Acquisition Corp. V
Valuation N/A
Consumer Cyclical
Price$11.52
Model IV—
P/IV—
Limited data — see page
LOMA
Loma Negra Compania Industrial Argentina Sociedad Anonima
Valuation N/A
Industrials Risk 48 · Elevated
Price$9.75
Model IV—
P/IV—
Limited data — see page
LONA
LeonaBio, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$6.92
Model IV—
P/IV—
Limited data — see page
LOOP
Loop Industries, Inc.
Valuation N/A
Basic Materials Risk 27 · Moderate
Price$0.47
Model IV—
P/IV—
Market implies +18.0%/yr vs model +5.0% · above model
LOT
Lotus Technology Inc.
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$1.09
Model IV—
P/IV—
Market implies +33.8%/yr vs model +8.0% · above model
LPA
Logistic Properties of the Americas
Valuation N/A
Real Estate Risk 34 · Moderate
Price$3.38
Model IV—
P/IV—
Limited data — see page
LPAA
Launch One Acquisition Corp.
Valuation N/A
Financial Services
Price$10.76
Model IV—
P/IV—
Limited data — see page
LPBB
Launch Two Acquisition Corp.
Valuation N/A
Financial Services
Price$10.82
Model IV—
P/IV—
Limited data — see page
LPCN
Lipocine Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.27
Model IV—
P/IV—
Market implies +34.8%/yr vs model +2.0% · above model
LPCV
Launchpad Cadenza Acquisition Corp I
Valuation N/A
Financial Services
Price$10.07
Model IV—
P/IV—
Limited data — see page
LPLA
LPL Financial Holdings Inc.
Valuation N/A
Financial Services Risk 62 · High
Price$345.66
Model IV—
P/IV—
Market implies +36.1%/yr vs model +8.0% · above model
LPRO
Open Lending Corp
Valuation N/A
Financial Services Risk 54 · Elevated
Price$3.14
Model IV—
P/IV—
Market implies +46.1%/yr vs model +2.0% · above model
LPTH
LIGHTPATH TECHNOLOGIES INC
Valuation N/A
Technology Risk 36 · Moderate
Price$9.20
Model IV—
P/IV—
Market implies +65.6%/yr vs model +2.0% · above model
LRE
LEAD REAL ESTATE CO., LTD
Valuation N/A
Industrials Risk 58 · Elevated
Price$1.27
Model IV—
P/IV—
Limited data — see page
LRMR
Larimar Therapeutics, Inc.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$3.92
Model IV—
P/IV—
Limited data — see page
LSCC
LATTICE SEMICONDUCTOR CORP
Valuation N/A
Technology Risk 49 · Elevated
Price$119.76
Model IV—
P/IV—
Market implies +61.6%/yr vs model +2.0% · above model
LSPD
Lightspeed Commerce Inc.
Valuation N/A
Technology Risk 42 · Elevated
Price$10.11
Model IV—
P/IV—
Limited data — see page
LSTA
LISATA THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.63
Model IV—
P/IV—
Market implies +49.0%/yr vs model +15.0% · above model
LTBR
LIGHTBRIDGE Corp
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$6.66
Model IV—
P/IV—
Market implies +75.0%/yr vs model +5.0% · above model
LTRN
Lantern Pharma Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.70
Model IV—
P/IV—
Limited data — see page
LU
Lufax Holding Ltd
Valuation N/A
Financial Services Risk 46 · Elevated
Price$1.21
Model IV—
P/IV—
Limited data — see page
LUD
Luda Technology Group Ltd
Valuation N/A
Basic Materials Risk 40 · Elevated
Price$4.25
Model IV—
P/IV—
Market implies +32.7%/yr vs model +0.0% · above model
LUMN
Lumen Technologies, Inc.
Valuation N/A
Communication Services Risk 42 · Elevated
Price$6.94
Model IV—
P/IV—
Market implies +18.3%/yr vs model -3.3% · above model
LUNR
Intuitive Machines, Inc.
Valuation N/A
Industrials Risk 60 · High
Price$14.35
Model IV—
P/IV—
Market implies +107.3%/yr vs model +15.0% · above model
LUXE
LuxExperience B.V.
Valuation N/A
Consumer Cyclical Risk 32 · Moderate
Price$7.39
Model IV—
P/IV—
Limited data — see page
LVO
LiveOne, Inc.
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$3.83
Model IV—
P/IV—
Market implies +18.6%/yr vs model +15.1% · above model
LVWR
LiveWire Group, Inc.
Valuation N/A
Consumer Cyclical Risk 62 · High
Price$1.10
Model IV—
P/IV—
Market implies +43.1%/yr vs model +2.0% · above model
LWAC
LightWave Acquisition Corp.
Valuation N/A
Financial Services
Price$10.32
Model IV—
P/IV—
Limited data — see page
LWLG
Lightwave Logic, Inc.
Valuation N/A
Consumer Cyclical Risk 42 · Elevated
Price$5.23
Model IV—
P/IV—
Market implies +150.0%/yr vs model +50.0% · above model
LXEH
Lixiang Education Holding Co. Ltd.
Valuation N/A
Consumer Defensive Risk 27 · Moderate
Price$1.79
Model IV—
P/IV—
Market implies +96.2%/yr vs model +2.0% · above model
LXEO
Lexeo Therapeutics, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$4.25
Model IV—
P/IV—
Market implies +92.4%/yr vs model +15.0% · above model
LXRX
LEXICON PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$2.00
Model IV—
P/IV—
Market implies +43.9%/yr vs model +15.0% · above model
LYEL
Lyell Immunopharma, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$11.96
Model IV—
P/IV—
Market implies +150.0%/yr vs model +2.0% · above model
LZM
Lifezone Metals Ltd
Valuation N/A
Basic Materials Risk 44 · Elevated
Price$3.93
Model IV—
P/IV—
Limited data — see page
MACI
Melar Acquisition Corp. I/Cayman
Valuation N/A
Technology
Price$11.00
Model IV—
P/IV—
Limited data — see page
MAGH
Magnitude International Ltd
Valuation N/A
Industrials Risk 38 · Moderate
Price$6.76
Model IV—
P/IV—
Limited data — see page
MAIA
MAIA Biotechnology, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.30
Model IV—
P/IV—
Limited data — see page
MAIN
Main Street Capital CORP
Valuation N/A
Unknown Risk 54 · Elevated
Price$56.22
Model IV—
P/IV—
Limited data — see page
MAIR
Madison Air Solutions Corp
Valuation N/A
Industrials Risk 44 · Elevated
Price$23.90
Model IV—
P/IV—
Limited data — see page
MAKO
Mako Mining Corp.
Valuation N/A
Basic Materials
Price$10.18
Model IV—
P/IV—
Limited data — see page
MAMK
MaxsMaking Inc.
Valuation N/A
Consumer Cyclical
Price$13.00
Model IV—
P/IV—
Limited data — see page
MANE
Veradermics, Inc
Valuation N/A
Healthcare Risk 37 · Moderate
Price$103.89
Model IV—
P/IV—
Limited data — see page
MANU
Manchester United plc
Valuation N/A
Communication Services
Price$20.05
Model IV—
P/IV—
Limited data — see page
MARA
MARA Holdings, Inc.
Valuation N/A
Financial Services Risk 64 · High
Price$11.98
Model IV—
P/IV—
Market implies +92.1%/yr vs model +24.8% · above model
MARPS
MARINE PETROLEUM TRUST
Valuation N/A
Financial Services
Price$4.51
Model IV—
P/IV—
Limited data — see page